Williams actually does not even know what Vascepa is.
What a dimwit. Absolute moron.
Here are just a few of his insightful comments that I saw just skimming through his posts.
He doesn't know that Vascepa is refined fish oil, just like PlusEPA or any other pharmaceutical grade fish oil. He thinks magic wizards create Vascepa in a lab out of mystery ingredients and he puts down anything that comes from a fish. Fishbreath?
Just one more example of the extreme dolts inhabiting this message board.
• williams4076 Re: CAN I BUY - EPA with NO DHA today? 4-Jul-12 06:29 pm
Plus EPA is made from the fish in the sea, correct?
AMR101 is chemically engineered by a pharmaceutical company.
With the Anchor and Marine indication, Plus EPA wouldn't pass the purity or supply demand for the REAL pharmaceutical grade AMR 101.
Today the International Atherosclerosis Society (IAS) and Pfizer Independent Grants for Learning & Change (IGLC) announce their collaboration on a new grant opportunity focused on improving care for patients around the world with medium or high levels of cardiovascular risk, with a particular focus on dyslipidemia.
Lipitor sales have started to slide in Europe, Pfizer offered a grant for a big idea...I think they might have an idea already. IAS had a presence at The 2013 Cardiometabolic Health Congress (CMHC), Vascepa's coming out party.
A little more about the 2013 CMHC:
"Despite a vast armamentarium of drugs for lowering glucose, reducing blood pressure , and improving lipid profiles, significant numbers of patients with diabetes are at high risk for cardiovascular events. In fact, patients with diabetes are two- to four-times more likely than those without to suffer from cardiovascular disease.
In the new CMHC symposium entitled, Getting to the Heart of Diabetic Dyslipidemia in High-Risk Patients: Clinical Dilemmas & Novel Approaches to Cardiovascular Risk Reduction, world-renowned faculty, Drs. Darren McGuire, Sunder Mudaliar, Jorge Plutzky, and Jean-Claude Tardif, will explain the rationale for early and aggressive treatment of both glucose and lipids in patients with type 2 diabetes in order to reduce cardiovascular risk. Our faculty will also evaluate clinical trial data on available and emerging therapeutic agents aimed to achieve these goals."